18 May 2021 • Clinical Capabilities
Rotterdam, the Netherlands, VIROCLINICS-DDL is pleased to announce the signing of a renewal for collaboration agreement with REPROCELL. REPROCELL will provide sample processing services to VIROCLINICS-DDL to support several clinical research projects.Read more →
21 April 2021 • Life Sciences
REPROCELL USA and REPROCELL Europe will be attending all 5 days of the Biotechgate Digital Partnering 2021 Event, 3-7 May 2021.
Partnering scheduling is now open, and registration is free.
Have a one-on-one Zoom meeting with our experts and get to know our capabilities of life sciences.
We may be a good partner for you in your research projects! We have included an overview of our available services below:Read more →
19 April 2021 – Bioserve Biotechnologies India Pvt. Ltd. launches clinical oncology diagnostic services in India.
19 April 2021 • Clinical Capabilities
Hyderabad India – 19 April 2021: Bioserve Biotechnologies India Pvt Ltd, a 100% owned subsidiary of REPROCELL Inc, is pleased to announce the launch of clinical oncology diagnostic service in India. This new service is clinician-friendly, aiming to deliver comprehensive, NGS-based genomic profiling in oncology targeting a wide range of cancers. The company also provides pharmacogenomics testing using single gene panels, offering researchers detailed interpretations and recommendations that provide powerful insights for the development of targeted therapies.Read more →
8 April 2021 • Clinical Capabilities
We are pleased to announce that on Tuesday 6th April 2021, REPROCELL launched a new testing service for the identification for Covid-19 variants using the Allplex SARS-CoV-2 Variants I Assay (referred to below as Allplex) manufactured by Seegene Inc. (South Korea). This will be offered in addition to full screening test for Covid-19 using cutting-edge SmartAmp technology that REPROCELL launched on March 1st 2021.Read more →
REPROCELL collaborates with Blacktrace Holdings in the sales of Nadia series, single-cell analysis system, in Japan
22 March 2021 • Clinical Capabilities
YOKOHAMA, 22 March, 2021/ REPROCELL has initiated a collaboration with Blacktrace Holdings Ltd in the sales of their Nadia series: a single-cell analytical system, in Japan.Read more →
REPROCELL Regenerative Medicine Center officially certified as a manufacturing facility for cell culture products
17 March 2021 • Clinical Capabilities
YOKOHAMA, March 16, 2021/ We are pleased to announce that our cell processing facility, REPROCELL Regenerative Medicine Center (located in Life Innovation Center in the Kanagawa region), was certified as manufacturing facility for cell culture products (registration number: FA3200006) on March 8th, 2021 by Kanto-Shinetsu Regional Bureau of Health and Welfare.Read more →
Hoth Therapeutics Executes Partnership Agreement with REPROCELL to Assess the Effect of HT-003 Therapeutic Platform on Inflammatory Bowel Disease
15 March 2021 • Drug Discovery
NEW YORK, March 11, 2021/PR Newswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has executed a partnership agreement with REPROCELL, a contract research organization (CRO), providing a unique combination of products and services to power translational research, to assess the effect of the HT-003 therapeutic platform on tissue from ulcerative colitis and Crohn’s disease patients. Fresh explants of ulcerative colitis and Crohn’s disease tissues obtained from surgical resection will be used as the test systems to investigate the therapeutic potential of the HT-003 drugs via measurement of key biomarkers for these diseases. All testing will be performed by REPROCELL.Read more →
11 March 2021 • Clinical Capabilities
Hyderabad India – 11 March 2021: Bioserve Biotechnologies Pvt Ltd, 100% owned subsidiary of REPROCELL Inc, is pleased to announce the launch of Non-Invasive Prenatal Testing (NIPT) services in India.Read more →
New publication on RNA reprogramming of endothelial progenitor cells to make clinically -relevant iPSCs
1 March 2021 • Stem Cells
[Glasgow, UK] REPROCELL has contributed to a novel publication detailing advancements in induced pluripotent stem cell (iPSC) reprogramming. The paper, published in New Biotechnology by Dr Amer Rana and his team of researchers from the University of Cambridge, was in collaboration with Dr Sarah Eminli-Meissner, Head of Business for Stem Cell Research at REPROCELL. It describes techniques for reprogramming blood-derived cells endothelial progenitor cells, or “EPCs”, into iPSCs.Read more →
[Yokohama, Japan] REPROCELL will launch a new PCR testing service for COVID-19 from March 2021 in collaboration with DNAFORM Inc: a Japanese start-up company based on cutting-edge technologies developed by RIKEN, Japan’s largest comprehensive research institute.Read more →